Is Revium Rx halal to invest in?

According to Musaffa's Shariah screening methodology, Revium Rx (RVRC) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Revium Rx a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Revium Rx using these criteria to determine its compliance status.

Can Muslims buy shares of Revium Rx?

Muslim investors may consider investing in Revium Rx if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Revium Rx classified as NOT COVERED?

Musaffa determines the Shariah status of Revium Rx by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Revium Rx updated?

The Shariah compliance status of Revium Rx may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Revium Rx become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Revium Rx?

You can check the latest Shariah compliance status of Revium Rx on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Revium Rx. Stock Analysis RVRC

United States N/A Micro Cap

Revium Recovery, Inc. is a biotechnology company focused on the development of highly effective lipid-based therapies that redefine treatment standards. is a pre-clinical stage biopharmaceutical company. The company develops technologies and drug-delivery technological platforms. Its pipeline encompasses antibiotics for antimicrobial-resistant bacteria, immune checkpoint inhibitor adjuvant for solid tumors, and an immunization platform. The Company, through its subsidiary, LipoVation Ltd., develops a portfolio of NLP-based pharmaceutical candidates and plans to complete the development and commercialization of a series of medical technologies including: Nanoparticles-based formulation of a potent antibiotic which, based on in vitro and in vivo animal models studies, shows promising potential in combating severe life-threatening antibiotic-resistant bacteria (Nano-Mupirocin); Novel adjuvant to cancer therapies: a nanoparticles-based formulation of angiotensin receptor blockers for intravenous administration (Nano-Candesartan), and Liposomal Protein-Loaded Technology - an approach in immunization through nano particle-based vaccines.

Key Statistics of Revium Rx (RVRC)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$1.67$1.67

Today's Open

$1.67

Volume

101.00

P/E Ratio (TTM)

52 Week Range

$0.52$1.67

Market Cap

101.42M

Avg. Volume